The global market for therapeutic apheresis is forecasted to attain USD 2,922.7 million by 2025, expanding at 3.9% CAGR to reach USD 4,285.0 million by 2035. In 2024, the revenue of therapeutic apheresis was around USD 2,815.7 million.
Due to the wider availability of portable and easy to use devices for transfusion treatments, the use of therapeutic apheresis is also rising. Thermo-apheresis devices will find a broad usability framework applicability in resource-constrained areas such as rural areas and rapidly developing regions that may lack advanced healthcare provisions.
Less weight and a compact design of such devices make setting up and transporting easy, enabling patients located in faraway areas to receive such essential treatments instead of having to travel for specialized facilities. This kind of accessibility is crucial for achieving timely and effective treatment, especially for chronic illness patients who need recurrent apheresis procedures.
Global Therapeutic Apheresis Industry Analysis
| Attributes | Key Insights |
|---|---|
| Industry Size (2025E) | USD 2,922.7 million |
| Industry Value (2035F) | USD 4,285.0 million |
| CAGR (2025 to 2035) | 3.9% |
Having access to on-site apheresis treatments during emergencies can be a lifesaver. Many outpatient and home-based treatments as a way of saving money and increasing convenience for the patients. This movement would not have been possible without portable apheresis equipment allowing treatments to occur outside of the hospital.
Such treatments, allowed by these devices in the comfort of their patients' homes or even at outpatient clinics, mean that not only has the burden on the hospitals been lessened, but the quality of the patients' lives has also improved. Their ease promotes a patient-oriented approach to treatment whereby the treatment compliance is improved, thereby enhancing the general health outcomes.
One of the major complications post-kidney transplantation is antibody-mediated rejection, which can be duly managed by the use of therapeutic apheresis.
By removing DSAs and other noxious immune components, therapeutic apheresis helps decrease the immunological response against the substitute organ.
Recently, therapeutic apheresis has been increasingly used as an adjuvant treatment in renal transplantation, suggesting perhaps a paradigm shift toward more personalized, interdisciplinary treatments to improve patient management and graft outcomes.
Explore FMI!
Book a free demo
A comparative analysis of fluctuations in compound annual growth rate (CAGR) for the therapeutic apheresis industry outlook between 2024 and 2025 on a six-month basis is shown below.
By this examination, major variations in the performance of these markets are brought to light, and trends of revenue generation are captured hence offering stakeholders useful ideas on how to carry on with the market’s growth path in any other given year.
January through June covers the first part of the year called half1 (H1), while half2 (H2) represents July to December.
The table below illustrates therapeutic apheresis market compound annual growth rate (CAGR) comparison between 2024 and 2025 H1 half year CAGR. In summary, this revenue growth report also provides a general idea of the market as a whole. H1 is from January to June, whereas H2 is from July to December.
For H1 of the decade, i.e. 2024-2034, the company is projected to grow at a CAGR of 3.9%, meanwhile in H2 of the same decade, it is going to grow at a CAGR of 4.5%.
| Particular | Value CAGR |
|---|---|
| H1 | 3.9% (2024 to 2034) |
| H2 | 4.5% (2024 to 2034) |
| H1 | 3.9% (2025 to 2035) |
| H2 | 4.3% (2025 to 2035) |
Moving onto the next period, which is H1 2025 to H2 2035, the CAGR is now reduced marginally to 3.9% in the first half and is expected to slightly lower at 4.3% in the second half. It remained the same in the first half (H1) at 0.0 BPS, whereas in the second half (H2), it declined by 16.0 BPS.
Growing Demand for Source Plasma Drives the Therapeutic Apheresis Market
The therapeutic apheresis market is witnessing rapid growth as a result in increasing need from end-users for plasma-derived biopharmaceuticals, which also increase source plasma demands. Particularly witness a rise in number of collectors and specialized source plasma collecting centers with increasing application of therapies that mandate utilization of large volumes of plasma.
Biotechnological innovations and the surge in the incidence and prevalence of chronic and rare diseases will fuel the increased growth rate in the plasma-derived biopharmaceuticals market. Immunoglobulins, albumin, clotting factors, and enzyme replacement therapies are products required for patients with autoimmune disorders, hemophilia, and immune deficiency, among others.
Thus, there is going to be a greater demand for those middle-source plasma donation therapies as therapeutic apheresis also propagates as a field in the need for consistent availability of such high-quality plasma.
The combination of educational campaigns directed at the realization of the significance of plasma donation, and donation drives and outreach initiatives, have raised donor participation rates in the field essentially driving the market.
Rising Rare Disease Management with Therapeutic Apheresis, Accelerating the Market
For many rare diseases, a specialized treatment option are being the primary choice for many healthcare professionals as well as the patients. Awareness and diagnosis of these rare conditions are developing, thus providing the unique opportunity for the apheresis provider to gain more exposure to the market.
The rare diseases are usually treated by combinations of healthcare providers, researchers, and patient advocacy groups working together across academic lines. Apheresis providers are thus able to partake in joint research efforts that enhance our understanding of, and ability to treat, uncommon diseases.
Collaboration between therapeutic apheresis providers and researchers along with advocacy groups will bring forth much-needed insight, data, and knowledge toward the development of novel treatments and treatment regimens for rare diseases. This should improve patient outcomes and quality of life.
This, results in an opportunity to the rare diseases and orphan indication patients in therapeutic apheresis market growth. The expansion of apheresis providers to offer treatment services is the means of meeting the unmet medical need, betterment of the outcome of patients, and their success in being at the top position as the service provider for the specific segment.
Development and Innovation of Pathogen Inactivation Technology Opens the Opportunities in the Market
The therapeutic apheresis market will be promisingly growing significantly owing to innovative technologies and advancement of pathogen inactivation. Safety for treatment with therapeutic apheresis could be secured if such procedures utilize pathogen inactivation technologies in proactive ways.
With these technologies, pathogen detection and inactivation-for example, that of viruses, bacteria, and parasites-become very efficient, thereby minimizing the risk of transfusion-transmitted infections (TTIs) and other infectious complications in the apheresis treatment. Therefore, with pathogen inactivation, therapeutic apheresis could be offered in settings not previously considered, especially in blood component therapy.
The advancement and novelty of pathogen inactivation technologies will fuel major growth for the therapeutic apheresis market. Then again, better care assurance, catalyzing a market revolution, and enhancing the chances of the apheresis players in the new healthcare landscape should progress through reconstructing safety protocols, extending application ranges, and facilitating partnership building.
The Market for Therapeutic Apheresis Is Severely Constrained By the Decreasing Transfusion Rates and Lack of Skilled Professionals
The transfusion rate reduction causes a big constraint on the therapeutic apheresis market. Advancements in medical treatments, such as non-transfusion-based therapies, have ultimately reduced the demand for blood transfusions and consecutively reduced the demand for apheresis procedures.
Non-reliability on apheresis treatment in some medical conditions increases the adoption of alternative treatment methods in hospitals and healthcare facilities.
Besides, strict regulations regarding blood and plasma collection operate as a barrier to market development. Regulatory requirements concerning donor eligibility, safety protocols, and quality control measures raise the complexity and cost of operations for blood centers and apheresis service providers. These factors make potential entrants shy away and retard market growth.
Another major restraint is the lack of skilled professionals to perform apheresis procedures. The nature of therapeutic apheresis is very specialized and requires trained personnel.
Workforce shortages limit service accessibility, especially in developing regions. High procedural costs and limited reimbursement policies further restrain market adoption since many healthcare providers and patients cannot afford it.
Added to that, public misconceptions and lack of awareness regarding plasma donation and apheresis bring low donor participation. Since there are not enough plasma donors, not as many life-saving plasma-derived therapies can be produced, restraining overall market growth. The biggest task, for sustainable market development, will thus remain to try overcoming these.
CAGR of the global therapeutic apheresis sector during the historical period comprised between 2020 and 2024 was 3.7%. Continuous and positive growth was recorded by the therapeutic apheresis diagnostics industry-this segment reached a value of USD 2,815.7 million in 2024 from USD 2,434.8 million in 2020.
Therapeutic apheresis, the past several decades of its history show growth driven by innovations in medical technology, a continually increasing incidence of autoimmune diseases, and demand for more customized therapy.
This industry began historically from applications within the realm of hematology with use of plasmapheresis in treatment for blood disorders. With further understanding in the field of immunology and neurology expanded application into the use in treatment for conditions like Guillain-Barr syndrome, myasthenia gravis, and multiple sclerosis. During the last decade, automation was also introduced into the apheresis procedure, with the treatment period shortened and made safer.
Outpatient venues and home-based apheresis offer enhanced accessibility to treatment options. This situation is now the main tentative trend in the future of therapeutic apheresis, alongside precision medicine, AI-assisted blood component analysis, and nanotechnology-based filtration techniques for ultra-specific targeting of diseased causative molecules.
Blockchain technologies could be implemented into donor-recipient matching for a major paradigm shift in transfusion safety and traceability. Moreover, regenerative medicine is likely to converge with apheresis, where stem-cell-based apheresis techniques could enhance treatment outcomes for degenerative diseases.
New advances in biodegradable and bioengineered membranes for selective filtration may further fine-tune the efficiency of therapies. Wearable apheresis devices will surely provide additional revolutionizing opportunities in chronic disease management, including continuous blood purification for hyperlipidemia.
As value-based healthcare continues to gain legroom on the priority list, the adaptations of the reimbursement model in favor of the more cost-effective method of apheresis therapy will facilitate its widespread acceptance throughout the globe. As precision and automation progress, the market will be enabled for a transformative jump, allowing new treatment opportunities for complex and rare disorders.
B. Braun Melsungen AG, Terumo Corporation, Fresenius Medical Care (Fresenius SE & Co. KGaA), and Baxter International, Inc. are dominating players in tier 1 and hold 54.1% of the market. These companies have widespread presence globally, high revenue, and strong control in the markets. By spending significantly on the research and development, to hold a strong position in the market.
They also participated in the collaborations with hospitals and research organizations and regulatory authorities.
Tier 2 firms consist of Baxter International, Inc., Asahi Kasei Corporation, and others with around 27.6% market share and are well established in specific regional markets. They are mid-sized firms with a regional or niche orientation, adding to the market but not at Tier 1 levels.
They can specialize in certain apheresis technologies, serve specific geographic markets, or concentrate on cost-efficient solutions. These Tier 2 organizations seek to build globally but cannot match the similar financial or scope of operations in Tier 1 companies.
The section below covers the therapeutic apheresis industry analysis for the sales for different countries. The analysis of market demand of the key countries in various regions of the globe is North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, and Middle East & Africa.
North America is expected to be dominated by the United States, which will post a CAGR of 3.7% during the period until 2035.In South Asia & Pacific, India is likely to post the highest CAGR in the market of 3.6% by 2035.
| Country | Value CAGR (2025 to 2035) |
|---|---|
| United States | 3.7% |
| Germany | 3.6% |
| China | 4.0% |
| India | 4.4% |
| South Korea | 3.8% |
The United States therapeutic apheresis market has a CAGR of 3.7% during the forecast period. The diseases such as neuroimmunological disease are increasing with the aging population due to higher environmental triggers, thus leading to a demand for more frequent plasmapheresis.
In addition, the continuous growth in usage of therapeutic apheresis for the treatment of different uncommon hematological disorders like TTP and sickle cell disease increases its acceptance rate. Due to the expansion in different specialty apheresis centers of hospitals and clinics, access is further being made easier.
The emergence of personalized medicine and targeted therapies also enhances the precision of apheresis, making it one of the preferred choices of treatment. Moreover, biopharmaceutical companies are studying apheresis as a technique for advanced drug delivery in antibody-based and gene therapies. This speaks to the use of apheresis with emerging biotherapeutics that are considered one of the factors for the reshaping of treatment paradigms and contributing to market growth.
In 2024, Germany held a dominant revenue in the Western Europe market and is expected to grow with a CAGR of 3.6%.
The growth of organ transplantation in Germany also fuels its therapeutic market for apheresis due to its increasing reliance on apheresis techniques in enhancing transplant success rates.
Germany has emerged as one of the most technologically advanced organ transplant sectors in Europe, thereby making way for plenty of kidney, liver, and heart transplants requiring regular apheresis before and after the procedures to eliminate the risk of rejections.
It is now a standard component in desensitization protocols of patients with high donor-specific antibodies, very much resulting in a significant reduction in organ rejection and better long-term outcomes.
There is also increasingly prevalent hypercholesterolemia and familial hyperlipidemia that support demand for LDL apheresis, a form of specialized therapy for very high-risk cardiovascular patients who are resistant to conventional lipid-lowering treatments. Another extremely emerging trend involves the therapeutic application of apheresis in immunoadsorption, especially with autoimmune diseases and hematological malignancies.
The robust biomanufacturing industry in Germany is also pushing the envelope for innovations in filtration membranes and adsorption columns, thereby making apheresis therapies safer and more effective. All these factors are further solidifying Germany's position as one of the leading European markets for therapeutic apheresis.
China holds a dominant value share in East Asia market in 2024 and will increase with a CAGR of 4.0% in the forecast period.
Therapeutic apheresis in China is expanding very fast due to the fact that the country has rising hematological diseases like leukemia, lymphoma, and aplastic anemia. The growth in the elderly population and change in lifestyle pattern of the Chinese is also influencing the increase in blood-related cancers and disorders for which apheresis treatment becomes inevitable.
Besides, the use of plasma-based treatments has picked up, with China becoming the world's biggest consumer of plasma-based treatments. The fast-rising plasma collection networks and further investments in plasma fractionation facilities around the country are yet another driver for more sophisticated apheresis procedures.
Another critical driver is the further increase of the role apheresis is gaining in the management of severe infectious diseases, especially with respect to sepsis and viral hemorrhagic fevers for which therapeutic plasma exchange is also being evaluated on its prospective life-saving merits.
In addition, China's rising interest in regenerative medicine further supports the usage of apheresis for extracting stem cells and cellular therapies. The applications that are evolving into the future would place China at the forefront as a major growth hub for the therapeutic apheresis market. The continuous technology advancement and the large-scale health infrastructure development continue to accelerate this expansion.
The section contains information about the leading segments in the industry. Based on procedure type, therapeutic plasma exchange are expected to account 41.3% of the global share in 2025.
| Procedure Type | Value Share (2025) |
|---|---|
| TPE (Therapeutic Plasma Exchange) | 41.3% |
The TPE process is trending more in the market due to its widespread usage in autoimmune and neurological illness treatment. In conditions such as Guillain-Barr syndrome, myasthenia gravis, and thrombotic thrombocytopenic purpura (TTP), this process becomes crucial for elimination of pathogenic antibodies, immune complexes, and toxins.
Growing incidence of these diseases, combined with the development in apheresis technology, is fueling demand for TPE. Automated systems and enhanced filtration methods are increasing procedural efficiency, safety, and availability. In addition, growing clinical evidence supporting TPE's efficacy in managing complex conditions is further encouraging its adoption.
As the plasma-based therapies turn more effective with passing time, it is natural for TPE to remain in pole position over apheresis procedure. Expansion into chronic management as well as in critical care supports its trend towards dominance of the market thus proving to be the key addition factor to this general growth experienced within the realm of therapeutic apheresis.
| By End User | Value Share (2025) |
|---|---|
| Hospitals | 47.8% |
The leading end-user within the therapeutic apheresis market would be a hospital, as most of the highly advanced medical infrastructures are being operated, equipped with several big-capacity apheresis units. Advanced procedures, such as TPE, red cell exchange, and leukapheresis, require both highly specialized machinery and skilled professions, which again are readily available within the premises of hospitals.
Almost all the apheresis treatments take place in these hospitals, as these centers are viewed as the best for treating very serious diseases such as autoimmune diseases, hematological diseases, and complications after transplantation. The existence of ICUs and multidisciplinary teams makes it possible to provide emergency treatment in potentially life-threatening conditions such as TTP and sepsis.
These hospitals are also increasingly integrating highly sophisticated automation in their apheresis systems, so that efficiency and patient safety are combined. Consequently, a huge demand has developed for treatment through apheresis, coinciding with technological advances and the widening scope of therapeutic indications, making it extremely likely that this segment will remain the leader into the future.
Within this marketplace for therapeutic apheresis, very-active major players are continuously in competition by providing innovations in the fields of automation of the procedures, improved filtration technologies, and incorporation with cell and gene therapies, which increases the effectiveness and accessibility of apheresis therapies.
The competitive market is represented by strategic partnerships, acquisitions, and regulatory approvals, along with an increase in the outpatient and home-based apheresis solutions market development. The environment is more competitive, but advances in automation, precision medicine, and decentralized care will nurture the market.
Recent Industry Developments in Therapeutic Apheresis Market
The global therapeutic apheresis industry is projected to witness CAGR of 3.9% between 2025 and 2035.
The global therapeutic apheresis industry stood at USD 2,815.7 million in 2024.
The global therapeutic apheresis industry is anticipated to reach USD 4,285.0 million by 2035 end.
China is expected to show a CAGR of 4.0% in the assessment period.
The key players operating in the global therapeutic apheresis industry include B. Braun Melsungen AG, Asahi Kasei Corporation, Baxter International, Inc., Fresenius Medical Care (Fresenius SE & Co. KGaA), Terumo Corporation, MEDICA S.P.A., Haemonetics Corporation, Cerus Corporation and Others
Epidemic Keratoconjunctivitis Treatment Market Overview – Growth, Trends & Forecast 2025 to 2035
Eosinophilia Therapeutics Market Insights – Trends & Forecast 2025 to 2035
Encephalitis Treatment Market - Growth & Future Trends 2025 to 2035
Edward’s Syndrome Treatment Market – Growth & Future Prospects 2025 to 2035
Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treatment Market – Trends & Therapeutic Advances 2025 to 2035
Electrophoresis Market Trends - Growth, Demand & Forecast 2025 to 2035
Therapeutic Apheresis Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
